Samsung Bioepis and Merck Launch Herceptin (trasuzumab) Biosimilar Ontruzant® in U.S.

Patterson Belknap Webb & Tyler LLP
Contact

Patterson Belknap Webb & Tyler LLP

This week, Samsung Bioepis announced the U.S. launch of Ontruzant® (trastuzumab-dttb), a biosimilar of Genentech’s Herceptin (trasuzumab).  Ontruzant® will be marketed and distributed in the U.S. by Merck.  This launch represents Samsung Bioepis’s first oncology biosimilar in the U.S. market.  Genentech’s Herceptin is a monoclonal antibody used to treat breast cancer and metastatic stomach cancer, first approved in 1998.  Genentech tried to block the market entry of Ontruzant® by suing for patent infringement, but Samsung Bioepis and Genentech reached a settlement in June 2019.

Ontruzant® joins prior trasuzumab biosimilars including Mylan and Biocon’s Ogivri™, which launched in December of 2019, and Amgen’s Kanjinti™, which launched in July of 2019.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP
Contact
more
less

Patterson Belknap Webb & Tyler LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.